Vetr downgraded shares of Teva Pharmaceutical Industries (NYSE:TEVA) from a buy rating to a hold rating in a research note published on Tuesday. They currently have $17.71 price objective on the stock.
Several other equities research analysts have also recently commented on the stock. Goldman Sachs boosted their price objective on shares of Teva Pharmaceutical Industries from $20.00 to $25.00 and gave the company a buy rating in a research report on Thursday, January 11th. Morgan Stanley raised shares of Teva Pharmaceutical Industries from an underweight rating to an equal weight rating and set a $18.00 price objective on the stock in a research report on Friday, December 15th. Royal Bank of Canada set a $11.00 price objective on shares of Teva Pharmaceutical Industries and gave the company a sell rating in a research report on Wednesday, November 29th. Cantor Fitzgerald set a $10.00 price objective on shares of Teva Pharmaceutical Industries and gave the company a hold rating in a research report on Thursday, December 14th. Finally, Susquehanna Bancshares reaffirmed a positive rating and issued a $24.00 price objective (up from $22.00) on shares of Teva Pharmaceutical Industries in a research report on Thursday, January 25th. Ten research analysts have rated the stock with a sell rating, fifteen have assigned a hold rating and seven have assigned a buy rating to the company. The company presently has an average rating of Hold and an average price target of $20.69.
Shares of Teva Pharmaceutical Industries (NYSE:TEVA) opened at $17.31 on Tuesday. The company has a market cap of $17,978.39, a price-to-earnings ratio of -1.06, a P/E/G ratio of 1.54 and a beta of 0.65. Teva Pharmaceutical Industries has a 52-week low of $10.85 and a 52-week high of $33.82. The company has a debt-to-equity ratio of 1.91, a current ratio of 0.86 and a quick ratio of 0.58.
Teva Pharmaceutical Industries (NYSE:TEVA) last posted its quarterly earnings data on Thursday, February 8th. The company reported $0.91 EPS for the quarter, beating the consensus estimate of $0.77 by $0.14. The business had revenue of $5.46 billion for the quarter, compared to analysts’ expectations of $5.29 billion. Teva Pharmaceutical Industries had a negative net margin of 72.66% and a positive return on equity of 16.43%. The firm’s revenue was down 15.9% compared to the same quarter last year. During the same period in the previous year, the firm posted $1.38 EPS. equities analysts predict that Teva Pharmaceutical Industries will post 2.3 earnings per share for the current fiscal year.
In other news, EVP Mark Sabag sold 5,050 shares of the business’s stock in a transaction dated Thursday, February 15th. The shares were sold at an average price of $19.68, for a total transaction of $99,384.00. Following the transaction, the executive vice president now directly owns 44,517 shares in the company, valued at approximately $876,094.56. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders have sold a total of 10,734 shares of company stock worth $204,795 over the last 90 days. 7.10% of the stock is owned by company insiders.
Institutional investors have recently added to or reduced their stakes in the company. Calton & Associates Inc. acquired a new position in shares of Teva Pharmaceutical Industries during the 4th quarter worth about $108,000. Fieldpoint Private Securities LLC acquired a new position in shares of Teva Pharmaceutical Industries during the 3rd quarter worth about $171,000. Global Financial Private Capital LLC acquired a new position in shares of Teva Pharmaceutical Industries during the 4th quarter worth about $193,000. Wetherby Asset Management Inc. acquired a new position in shares of Teva Pharmaceutical Industries during the 4th quarter worth about $197,000. Finally, Sigma Planning Corp acquired a new position in shares of Teva Pharmaceutical Industries during the 4th quarter worth about $214,000. Institutional investors own 58.19% of the company’s stock.
WARNING: This report was first published by The Lincolnian Online and is owned by of The Lincolnian Online. If you are reading this report on another site, it was illegally stolen and reposted in violation of United States & international copyright & trademark laws. The legal version of this report can be viewed at https://www.thelincolnianonline.com/2018/03/23/vetr-lowers-teva-pharmaceutical-industries-teva-to-hold.html.
About Teva Pharmaceutical Industries
Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.
To view Vetr’s full report, visit Vetr’s official website.
Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.